Last update Dec. 21, 2022
Limited compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Zalcitabine (ddC) is also known as
Zalcitabine (ddC) in other languages or writings:
Main tradenames from several countries containing Zalcitabine (ddC) in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 88 | % |
Molecular weight | 211 | daltons |
Protein Binding | 4 | % |
VD | 0.3 - 0.7 | l/Kg |
pKa | 14.67 | - |
Tmax | 2 | hours |
T½ | 2 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Antiretroviral. It is a cytidine derivative nucleoside analog reverse transcriptase inhibitor (NRTI) with antiviral activity against Human Immunodeficiency Virus (HIV). Oral administration every 8 hours.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data (low molecular weight and very low percentage of plasma protein binding) makes it likely that significant amounts will pass into breast milk.
Viral resistance appears easily and has frequent serious side effects (peripheral neuropathy, heart disease, liver disease, esophageal ulcers...) for which it has been withdrawn from the market in many countries.
During breastfeeding, other HIV/AIDS treatments are preferable.(Panel 2022)